"The most rewarding part of working here is to be able to not only do cutting edge science, but also see our research being tested in the clinic, and eventually benefit human patients."
I joined Genentech after my postdoc training at UCSF. Genentech was my first choice as I knew it was the best blend of academic and industry cultures.
The most rewarding part of working here is to be able to not only do cutting edge science, but also see our research being tested in the clinic, and eventually benefit human patients.
Science Signaling 5 (223): ra37.
My lab is interested in cancer signaling pathways and the development of novel therapeutic agents to target these pathways in cancer.
An area of our focus is the PI3K/Akt/mTOR signaling pathway. This is one of the most frequently activated pathways in human cancers, either as a result of activation of upstream growth factor signaling, gain of function of the key signaling nodes such as the lipid kinase PI3K or the protein serine/threonine kinase Akt, or loss of function of the negative regulators of the pathway such as the frequently lost tumor suppressor PTEN.
We use molecular, cellular and genetic approaches to investigate the function and regulation of key components of the pathway, which enables our rational design of therapeutic agents targeting this pathway, some of which are well into human clinical trials. These agents in turn provide us with valuable tools to further understand the molecular mechanisms of the pathway, and we are also actively investigating the mechanisms of resistance to these agents.